Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
KD501 as a New Therapeutic Agent for Dementia_ElcomScience
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
KD501 is a partially purified extract from Scrophulariae Radix, which shows an efficacy for the treatment of strokes and degenerated neuronal disease in vivo. Elcom filed an IND application with the KFDA (The Korea Food & Drug Administration) in May ...
Contact Yong U Kim
Participants
You
Email me a copy of this message

Introduction


Scrophulariae Radix (Scrophularia buergeriana)


- Selected in the screening of  neuroprotective and memory enhancing activity


- Used as anti-inflammation agent traditionally


- KD501 : 70% ethanolic extract of Scrophularia buergeriana root


- Standardized extract containing  phenyl propanoids and iridoids, as active ingredients


Memory enhancing activity of acute administration of KD501 on latency time of passive avoidance task in β-amyloid induced memory impairment mice. 






Technology Overview




The Company obtained tranditional herbal extract from Scrophulariae Radix and confirmed the in vitro neuroprotective effect and in vivo memory enhancing effect of the extract, and then identified the active ingredients of the extract. Elcom named the active ingredients KD501, which is a partially purified extract consisting of cinnamate derivates. Elcom holds patent rights for KD501 and the pharmaceutical use thereof.




The positive effect of KD501 on the performance of scopolamine-treated mice in the working memory trial of the water maze test.




 



Type of Business Relationship Sought
Out-Licensing
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
GOVERNMENT INSTITUTE